<unk>  is a tyrosine kinase inhibitor that is FDA approved for the treatment of gastrointestinal stromal tumor (GIST) after disease progression on or intolerance to imatinib mesylate, advanced renal cell carcinoma (RCC) and Progressive, well-differentiated pancreatic neuroendocrine tumors (pNET) in patients with unresectable locally advanced or metastatic disease. There is a Black Box Warning for this drug as shown here.  Common adverse reactions include fatigue, asthenia, fever, diarrhea, nausea, mucositis/stomatitis, vomiting, dyspepsia, abdominal pain, constipation, hypertension, peripheral edema, rash, palmar plantar erythrodysesthesia, skin discoloration, dry skin, hair color changes, altered taste, headache, back pain, arthralgia, extremity pain, cough, dyspnea, anorexia and bleeding.
Sunitinib
Ceritinib
Axitinib
Gilteritinib
Erdafitinib
Bosutinib
Baricitinib
Masitinib